Abiopharma

🔍 Jagid Jeffrey M (Director)

Company: ATLANTIC INTERNATIONAL CORP. (ATLN)

Report Date: 2026-01-01

Detailed Transactions and Holdings:

• Acquired 5,551,223 shares of Common Stock, $.00001 par value at $1.33 per share (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,221,025.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,000,000 shares of Incentive Stock Option at $1.33 per share (Derivative)
  Date: 2026-01-05 | Code: A | Expires: 2031-07-05 | Exercise: 2026-07-05 | equity_swap_involved: 0 | shares_owned_after: 1,000,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents shares of common stock vested upon exercise of restricted stock units awarded under the Issuer's 2025 Omnibus Equity Incentive Plan pursuant to Rule 16b-3 under the Securities Exchange Act of 1934. This does not represent a discretionary transaction by a reporting person. The total gross shares issued amounted to 5,551,223 shares. 1,665,367 shares were retained by the Company in order to cover any tax liability, resulting in a net amount of 3,885,856 being issued to the reporting person.
• F2: These shares were valued at $1.33 per share, the closing market price on December 31, 2025.
• F3: These options were granted under the Company's 2025 Equity Incentive Plan pursuant to Rule 16-b-3 under the Securities Exchange Act of 1934. They vest in their entirety six months from the date of grant.